RE-104

RE-104
Clinical data
Other names	RE-104; RE104; 4-Glutaryloxy-N,N-diisopropyltryptamine; 4-Hydroxy-N,N-diisopropyltryptamine O-glutarate; O-Glutaryl-4-hydroxy-N,N-diisopropyltryptamine; 4-HO-DiPT glutarate; O-Glutaryl-4-HO-DiPT; 4-GO-DiPT
Legal status
Legal status	Investigational;
Pharmacokinetic data
Elimination half-life	3-4 hours hours
Identifiers
	IUPAC name 1-[3-[2-[Bis(1-methylethyl)amino]ethyl]-1H-indol-4-yl] pentanedioate;
CAS Number	2756001-39-3 ;
PubChem CID	162510634;
UNII	64JU3Z4Q2;
Chemical and physical data
Formula	C21H30N2O
Molar mass	326.484 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N(CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O)C(C)C;
	InChI InChI=1S/C21H30N2O4/c1-14(2)23(15(3)4)12-11-16-13-22-17-7-5-8-18(21(16)17)27-20(26)10-6-9-19(24)25/h5,7-8,13-15,22H,6,9-12H2,1-4H3,(H,24,25); Key:LSDOIAGGRBGDJJ-UHFFFAOYSA-N;

RE104, formerly known as FT-104, and as 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate or 4-GO-DiPT), is an investigational drug product being developed by the pharmaceutical company Reunion Neuroscience. RE104 a prodrug ester of a synthetic psychedelic 4-hydroxytryptamine, 4-HO-DiPT. It is one of a number of related psychedelic derivatives being developed as pharmaceuticals to treat mood disorders.

RE104 is in human clinical trials as a possible treatment for postpartum depression and treatment-resistant depression. As of 2024, RE104 entered a Phase II clinical trial for post-partum depression.